We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Quick Test for HIV/AIDS Being Developed

By HospiMedica staff writers
Posted on 17 Apr 2007
Scientists are working to develop a quick, simple, and cheap immune-system test for people in the developing world. More...
It could help HIV (human immunodeficiency virus) /AIDS sufferers in the poorest countries get appropriate treatment to extend their lives, possibly by as much as 10 to 15 years.

The work is part of an US$8.6 million international consortium, called the CD4 Initiative, led by Imperial College (London, UK) and funded by the Bill and Melinda Gates Foundation. Antje J. Baeumner, Cornell University (Ithaca, NY, USA) associate professor of biological and environmental engineering, has been awarded an initial $386,000 (subject to annual renewal for four years) from the consortium to determine a way to simply assess the critical HIV/AIDS immune system factors--CD4 T-cell count or CD4+ T-lymphocytes count--in the blood.

When patients are infected with HIV/AIDS, the number of circulating CD4 T-cells drops significantly, said Prof. Baeumner. If they get the appropriate retroviral treatment, their life span can be increased by many years. CD4 counts assist in the decisions on when to initiate and when to stop the treatment, which makes this test so important. While such testing is routine in Western countries--and used repeatedly over the course of treatment to see if interventions are effective--it's unavailable to many people in the developing world, especially in rural areas.

For the first two years, Prof. Baeumner will work on developing a test for CD4+ T-lymphocytes in the blood that can be likened to a pregnancy test using biosensor nanovesicles (microscopic, fluid-filled pouches made of phospholipids that can deliver drugs--also known as liposomes) to enhance the signal. Several other consortium organizations also are working on similar product development so that the best possible test can be developed in the shortest time possible.

Currently, most people in the world, such as those in third world countries, infected with HIV have no access to detection technology, explained Prof. Baeumner, noting that 40 million people live with HIV/AIDS worldwide, many of them in areas where electricity is unreliable or nonexistent, water quality is poor, and there are few, if any, highly skilled health-care technicians. This test, however, is being developed to endure harsh temperature conditions and be truly simple--no batteries will be needed, for example.


Related Links:
Cornell University
Imperial College

Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Surgical Dressing
ALLEVYN Ag+ SURGICAL
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: New findings show that chemotherapy plus immunotherapy before surgery produced greater tumor destruction than immunotherapy alone in head and neck cancer patients (Image Credit: Adobe Stock)

Combination Therapy Before Surgery Drives Stronger Tumor Reduction in Head and Neck Cancer

Patients with head and neck cancer who are scheduled for surgery often face a waiting period with limited treatment, creating an opportunity to reduce viable tumor burden before the operation.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.